• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Join the Alliance

The International Alliance of ALS/MND Associations encourages all organizations involved in support of people living with ALS/MND or have an interest in ALS/MND to apply for membership.

The Alliance offers three types of membership: Full, Affiliate, and Honorary. Each has its own criteria, application requirements, and fees.

Membership Criteria, Application Requirements & Fees

Full Membership

To qualify for Full Membership, an organization must:

  • Serve people with ALS/MND or related disorders with a focus on patient care, advocacy and/or research;
  • Be chartered in their own country as a non-profit national or independent organization for at least 2 years;
  • Have a legal constitution or by-laws;
  • Be governed by a volunteer Board of Directors (however described), elected by and/or from the membership which includes people living with ALS/MND, carers, past carers, or people closely associated with the disease; and
  • Prepare an annual financial statement.

Applicants for Full Membership must submit the following documents in English:

  • Cover letter stating their reasons for wanting to become a member of the Alliance
  • Proof of non-profit status in their country
  • Copy of their constitution and/or by-laws
  • List of names of the Board of Directors (however described) and Officers
  • Mission or purpose statement of the organization
  • Written financial statement of previous year’s income
  • Copies of or weblinks to brochures and other materials (if not in English, then with some English translation)

The fee for Full Membership is either an amount equal to 0.2% of total annual income of the applicant organization or £100 (Pounds Sterling), whichever is greater. At the discretion of the Board of Trustees, fees can be waived or reduced for members that demonstrate need and make a request in writing.

Affiliate Membership

Affiliate Membership in the Alliance falls within four categories:

  1. Emerging Associations Affiliate: New ALS/MND Associations being established or recently chartered in own country as a non-profit organization (or status pending) by July 1st of the current membership year.
  2. Network Affiliate:
    1. Regional non-profit networks of researchers and clinicians collaborating on ALS/MND
    2. Regional non-profit patient networks providing resources and support to people living with ALS/MND
    3. Non-profit neurological alliances advocating for and supporting people with neurological conditions
  3. Education and Research Affiliate: Education or research institutes and centres dedicated to ALS/MND that operate within a non-profit entity such as a university.
  4. Fiscal Sponsorship/Hosting Arrangement Affiliate: Organizations focused on ALS/MND that are not independently chartered and operate under the legal or administrative framework of a sponsoring or host organization.

To qualify for Affiliate Membership, an organization must:

  • Serve people with ALS/MND or related disorders with a focus on patient care, advocacy and/or research;
  • Be formally established in their own country as a non-profit organization, operate within a non-profit entity, or function under the legal or administrative structure of a sponsoring/host organization;
  • Be governed directly or indirectly by a legal constitution or by-laws;
  • Be governed by a volunteer Board of Directors (however described), elected by and/or from the membership that includes people living with ALS/MND, carers, past carers, or people closely associated with the disease; and
  • Prepare an annual financial statement (where administratively relevant).

Applicants for Affiliate Membership must submit the following documents in English:

  • Cover letter stating their reasons for wanting to become a member of the Alliance
  • Proof of non-profit status in their country
  • Copy of their constitution and/or by-laws
  • List of names of the Board of Directors (however described) and Officers
  • Mission or purpose statement of the organization
  • Written financial statement of previous year’s income (only for Emerging Associations, if available, and Network Affiliates)
  • Copies of or weblinks to brochures and other materials (if not in English, then with some English translation)

The fee for Affiliate Membership is £100 (Pounds Sterling). At the discretion of the Board of Trustees, fees can be waived or reduced for members that demonstrate need and make a request in writing.

Honorary Membership

Honorary Membership is awarded at the discretion of the Alliance’s Board of Trustees to individuals who have made significant contributions to the Alliance’s mission of a world free of ALS/MND. This may include former Board Members, Patrons, Staff, or Award recipients.

 

For any questions or to apply for membership, please contact the CEO at alliance@als-mnd.org.

The Board reviews applications quarterly. You will be notified of the decision by email.

We encourage prospective members to attend the Alliance Meeting. Observer status will be granted.

Primary Sidebar

  • Diana Fernandez, Argentina

    Diana Fernandez, Argentina

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Jean Waters, UK

    Jean Waters, UK

  • Anderson Custodio Pinto, Brazil

    Anderson Custodio Pinto, Brazil

  • Lee Millard, England

    Lee Millard, England

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Rolf Mauch, Switzerland

    Rolf Mauch, Switzerland

  • Gisli Jonasson, Iceland

    Gisli Jonasson, Iceland

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Ching-Liang Chu, Taiwan

    Ching-Liang Chu, Taiwan

  • Dan Doctoroff, USA

    Dan Doctoroff, USA

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • Alfredo Santos, Colombia

    Alfredo Santos, Colombia

  • John Dinon, Australia

    John Dinon, Australia

  • Chirag Walia, India

    Chirag Walia, India
    ChiragWalia

  • Duncan Bayly, Australia

    Duncan Bayly, Australia

  • Ann Nicol, USA

    Ann Nicol, USA

  • JP

    JP

  • Frank Bos, Netherlands

    Frank Bos, Netherlands

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Shay Rishoni, Netherlands

    Shay Rishoni, Netherlands

  • Timmy, Belgium

    Timmy, Belgium

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Len Johnrose, England

    Len Johnrose, England

  • Hollister

    Hollister
    hollister

  • Soledad Rodriguez, Spain

    Soledad Rodriguez, Spain

  • Tso-Ta Huang, Taiwan

    Tso-Ta Huang, Taiwan

  • Olga Cosentino, Argentina

    Olga Cosentino, Argentina

  • Brian Parsons, Canada

    Brian Parsons, Canada

  • Jose Rivero Muñoz, Mexico

    Jose Rivero Muñoz, Mexico

  • Claudia Cominetti, Italy

    Claudia Cominetti, Italy

  • John Russo, USA

    John Russo, USA
    final3878

  • Paul Launer, USA

    Paul Launer, USA

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Kirsten Harley, Australia

    Kirsten Harley, Australia

  • Murat Morali, Turkey

    Murat Morali, Turkey

  • Ali Var, Turkey

    Ali Var, Turkey

  • Mike Cels, Canada

    Mike Cels, Canada

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Jon Newsome, USA

    Jon Newsome, USA

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Danny Reviers, Belgium

    Danny Reviers, Belgium
    DannyReviers

  • Federica Mastrosimone, Italy

    Federica Mastrosimone, Italy

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • Malcolm Buck, Australia

    Malcolm Buck, Australia

  • Margarita Pizarro, Argentina

    Margarita Pizarro, Argentina

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login